Tablet Health review

This catalog gets the important thing right. Both molecules are sold in an oral form as well as an injection, and in both cases the oral form is cheaper — substantially so on the dual agonist. That is the arrangement you should want if you are deliberately holding a low dose, because the route that makes a small dose easiest to measure is also the one that costs least, and it is the reverse of how most of this category prices the same choice. Two things undercut the presentation. The first is the headline figure, which does not correspond to anything on the page: the site advertises flat monthly pricing starting at a number below every product it lists, so arriving on that figure you will not find it attached to a purchasable item anywhere in the catalog. Whether a cheaper product exists elsewhere is not something the page establishes. The second is the wording around it. Flat pricing and starting-at pricing are different promises — one says the number will not move, the other says it is the lowest it goes — and this page makes both at once about the same set of figures, which leaves you unable to tell whether the price you see is what you keep paying as a dose rises. No milligram appears anywhere, so that question cannot be settled from the catalog either.

Vs median

$10/mo above the $169 median across the 242 of 373 programs we track that publish a plain monthly rate

Market

$59–$1300/mo is the full published spread in our ranking

Structure

Standard plan, self-directed low dose

Consult

Included in the price

Dietitian

Not included

Labs

Not required

Pricing

Varies by dose, plan or tier

Price last updated

August 2026

Tablet Health does not publicly identify the pharmacy that fills its prescriptions. No bloodwork is required before you start. A clinician review is included in the price.

This catalog gets the important thing right. Both molecules are sold in an oral form as well as an injection, and in both cases the oral form is cheaper — substantially so on the dual agonist. That is the arrangement a reader deliberately holding a low dose should want, because the route that makes a small dose easiest to measure is also the one that costs least, and it is the reverse of how most of this category prices the same choice. Two things undercut the presentation. The first is the headline figure, which does not correspond to anything on the page: the site advertises flat monthly pricing starting at a number below every product it lists, so a reader arriving on that figure will not find it attached to a purchasable item anywhere in the catalog. Whether a cheaper product exists elsewhere is not something the page establishes. The second is the wording around it. Flat pricing and starting-at pricing are different promises — one says the number will not move, the other says it is the lowest it goes — and this page makes both at once about the same set of figures, which leaves a reader unable to tell whether the price they see is what they will keep paying as a dose rises. No milligram appears anywhere, so that question cannot be settled from the catalog either.

The advertised starting figure is below every product actually listed.

• It claims flat pricing and starting-at pricing about the same numbers.
• No dose sits behind any of the four figures.

Tablet Health is one of 373 low-dose GLP-1 programs we track, and 242 of them publish a monthly rate you can read before signing up. The ranking lists every published price on one screen, ordered with the companies that pay us first — a mechanism we state there, on the page it applies to.

Intentional GLP-1 microdosing is off-label and unproven — no randomized trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.

• What microdosing GLP-1 costs
• Oral semaglutide (Rybelsus)
• Microdosing tirzepatide
• The true annual cost of a plan
• What a flat price costs at a low dose